Connor, Clark & Lunn Investment Management (CC&L)’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-15,404
| Closed | -$28.5K | – | 1575 |
|
|
2023
Q1 | $28.5K | Buy |
+15,404
| New | +$28.5K | ﹤0.01% | 1206 |
|
|
2022
Q4 | – | Sell |
-144,885
| Closed | -$339K | – | 1483 |
|
|
2022
Q3 | $339K | Buy |
144,885
+18,812
| +15% | +$44K | ﹤0.01% | 893 |
|
|
2022
Q2 | $382K | Sell |
126,073
-45,051
| -26% | -$137K | ﹤0.01% | 830 |
|
|
2022
Q1 | $1.16M | Sell |
171,124
-3,614
| -2% | -$24.5K | 0.01% | 629 |
|
|
2021
Q4 | $1.46M | Buy |
174,738
+53,840
| +45% | +$450K | 0.01% | 606 |
|
|
2021
Q3 | $898K | Buy |
120,898
+48,302
| +67% | +$359K | ﹤0.01% | 663 |
|
|
2021
Q2 | $494K | Sell |
72,596
-12,599
| -15% | -$85.7K | ﹤0.01% | 791 |
|
|
2021
Q1 | $875K | Sell |
85,195
-9,734
| -10% | -$100K | ﹤0.01% | 719 |
|
|
2020
Q4 | $665K | Sell |
94,929
-5,457
| -5% | -$38.2K | ﹤0.01% | 688 |
|
|
2020
Q3 | $819K | Sell |
100,386
-79,178
| -44% | -$646K | 0.01% | 656 |
|
|
2020
Q2 | $1.24M | Sell |
179,564
-4,524
| -2% | -$31.2K | 0.01% | 562 |
|
|
2020
Q1 | $874K | Sell |
184,088
-2,400
| -1% | -$11.4K | 0.01% | 586 |
|
|
2019
Q4 | $1.63M | Sell |
186,488
-1,700
| -0.9% | -$14.8K | 0.01% | 459 |
|
|
2019
Q3 | $627K | Buy |
188,188
+12,050
| +7% | +$40.1K | ﹤0.01% | 627 |
|
|
2019
Q2 | $872K | Sell |
176,138
-8,100
| -4% | -$40.1K | 0.01% | 598 |
|
|
2019
Q1 | $1.14M | Buy |
184,238
+15,928
| +9% | +$98.7K | 0.01% | 503 |
|
|
2018
Q4 | $567K | Buy |
168,310
+38,780
| +30% | +$131K | ﹤0.01% | 672 |
|
|
2018
Q3 | $842K | Buy |
129,530
+53,955
| +71% | +$351K | ﹤0.01% | 597 |
|
|
2018
Q2 | $579K | Buy |
+75,575
| New | +$579K | ﹤0.01% | 743 |
|